Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesTreatment of prostate cancer cells with adenoviral vector-mediated antisense RNA using androgen-dependent and androgen-independent promoters
Medical Oncology, 06/16/09
Li W et al. - In a study to develop a novel antisense approach to prostate cancer (PC) therapy, it was found that both of the adenoviral vectors exhibited significant inhibitory effects on growth of prostate tumors, and the inhibitory effects of the pADxsi-P2-AdoMetDC-ODC-PolyA vector were stronger than those of the pADxsi-P1-AdoMetDC-ODC-PolyA vector.
Methods- ODC/AdoMetDC double antisense RNA recombinant adenovirus mediated by a prostate-specific androgen-dependent promoter (pADxsi-P2-AdoMetDC-ODC-PolyA) or a prostate-specific androgen-independent promoter (pADxsi-P1-AdoMetDC-ODC-PolyA) was constructed.
- Western blot analysis was performed to detect the ODC and AdoMetDC protein levels.
- Growth curves for each group of cells were determined by MTT assay.
- Flow cytometry was conducted to detect cell apoptosis, proliferation, and cell cycle distribution in order to demonstrate the effects of the recombinant adenoviruses on PC cells.
- RT-PCR, Western blotting, MTT, and tumor growth inhibition assay in nude mice demonstrated that pADxsi-P1-AdoMetDC-ODC-PolyA and pADxsi-P2-AdoMetDC-ODC-PolyA exhibited inhibitory effects on cell proliferation at both the gene and protein levels.
- Inhibiting effects of the pADxsi-P2-AdoMetDC-ODC-PolyA is more profound than those of the pADxsi-P1-AdoMetDC-ODC-PolyA vector.
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
What comes after docetaxel
Der Urologe, 11/18/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
What comes after docetaxel
Der Urologe, 11/18/09
Article Search
Sponsor